Articles

MDoutlook®: Delivers Precision Intelligence

MDoutlook® is pleased to share excerpts from the most recent MDoutlook’s OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Acute Myeloid Leukemia (AML). This research is the newest in a long line of impact studies following major data announcements in cancer. MDoutlook has covered the oncology space
Continue Reading
MDoutlook is growing and is looking for qualified Global Medical Analysts to join our enthusiastic team of disease experts. You can access the job posting here. Direct your resume and cover letter to [email protected] (only candidates; no recruiters please). We look forward to adding new stars to our team!
Continue Reading
Recently announced advances in the treatment of Multiple Myeloma (MM), for both newly diagnosed and relapsed / refractory patients, have been quickly embraced by oncologists globally. MDoutlook are pleased to share complimentary highlights from the most recent MDoutlook OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Multiple
Continue Reading
Speak with the cancer and commercialization experts at MDoutlook about answering your critical questions that arise throughout the life cycle of your brand or service. Oncology is an increasingly complex area, because of the rapidly evolving multi-disciplinary approach to disease management and the intricate diagnosis and treatment of this disease.
Continue Reading
Since 2008, MDoutlook has built the largest panel of verified cancer treaters in the world. Now at over 95,000 members strong, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer. MDoutlook offers clients a range of services powered by this proprietary oncology panel to
Continue Reading
MDoutlook is pleased to release the third report on the clinical impact of new data presented at ASCO and EHA 2015. This report includes analyses from 2 studies in hematologic malignancies involving more than 150 oncologists and hematologists with identified focus on Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).
Continue Reading
MDoutlook proudly presents the second study on the clinical impact of new data presented at ASCO 2015. This OncoPoll™ includes analyses from 2 studies in Gastrointestinal Cancers involving more than 160 oncologists. Our MD/PhD research team reports the following analysis highlights: Non-CRC GI Cancers Anti-PD-1 antibodies are expected to have
Continue Reading
MDoutlook celebrates its 8th consecutive year of syndicated research gauging the clinical impact of new data presented at ASCO 2015. Building on over 30 analyses since 2008, MDoutlook today releases the first analysis in a new series covering solid and liquid tumors. This OncoPoll™ focuses on the continued evolution of
Continue Reading
Since 2008, MDoutlook has built the largest panel of cancer treaters in the world. With more than 85,000 cancer treaters verified and profiled, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer. MDoutlook has developed a suite of offerings built on this proprietary oncology
Continue Reading
Built upon years of experience and appreciating the multi-factorial complexity of identifying and engaging ThoughtLeaders, MDoutlook has developed robust algorithms to capture all attributes of a ThoughtLeader's impact on the market. MDoutlook delivers 360° profiles of identified ThoughtLeaders, uniquely meshing public and proprietary data. Through our exclusive ThoughtLeader Attribute Dial™,
Continue Reading